[F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: Computed tomography in recurrent and metastatic cholangiocarcinoma

Journal of Computer Assisted Tomography

Volumn 31, Issue 2, 2007, Pages 223-228

  Jadvar, Hossein ^a   Henderson, Robert W ^a   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cholangiocarcinoma; FDG; PET; PET CT

Indexed keywords

CHEMOTHERAPY; COMPUTERIZED TOMOGRAPHY; DIAGNOSIS; ELECTRONS; POSITRONS; SURGERY;

CHOLANGIOCARCINOMA; COMPUTED TOMOGRAPHY SCAN; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE-POSITRON EMISSION TOMOGRAPHIES; FOLLOW UP; IMAGING EVALUATION; METASTATIC DISEASE; POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHIES; SIEMENS; STUDY GROUPS;

POSITRON EMISSION TOMOGRAPHY;

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LIVER PARENCHYMA; LYMPH NODE; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EID: 34147128671     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rct.0000237811.88251.d7     Document Type: Article

References (19)

1. Ahrendt SA, Nakeeb A, Pitt HA. Cholangiocarcinoma. Clin Liver Dis. 2001;5:191-218.
2. Yoon JH, Gores GJ. Diagnosis, staging and treatment of cholangiocarcinoma. Curr Treat Options Gastroenterol. 2003;6:105-112.
3. Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet. 2005;366:1303-1314.
4. Singh P, Patel T. Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr Opin Gastroenterol. 2006;22:294-299.
5. Zech CJ, Shoenberg SO, Reiser M, et al. Cross-sectional imaging of biliary tumors: current clinical status and future developments. Eur Radiol. 2004;14:1174-1187.
6. Townsend DW. From 3-D positron emission tomography to 3-D positron emission tomography/computed tomography: what did we learn? Mol Imaging Biol. 2004;6(5):275-290.
7. Lee JD, Yang WI, Park VN, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. J Nucl Med. 2005;46:1753-1759.
8. Kim YJ, Yun M, Lee WJ, et al. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1467-1472.
9. Anderson CD, Rice MH, Pinson CW, et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004;8:90-97.
10. Fritscher-Ravens A, Bohuslavizki KH, Broering DC, et al. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun. 2001;22:1277-1285.
11. Keiding S, Hanson SB, Rasmussen HH, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology. 1998;28:700-706.
12. Kluge R, Schmidt F, Caca K, et al. Positron emission tomography with [(18)F]fluoro-2-D-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001;33:1029-1035.
13. Kato T, Tsukamoto E, Kuge Y, et al. Clinical role of (18)F-FDG for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging. 2002;29:1047-1054.
14. Wakabayashi H, Akamoto S, Yachida S, et al. Significance of fluorodeoxyglucose PET imaging in the diagnosis of malignancies in patients with biliary stricture. Eur J Surg Oncol. 2005;31:1175-1179.
15. Reinhardt MJ, Strunk H, Gerhardt T, et al. Detection of Klatskin's tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET/CT: preliminary results for 22 patients. J Nucl Med. 2005;46:1158-1163.
16. Jadvar H, Conti PS. [F-18]-FDGPET and PET-CT in recurrent and metastatic cholangiocarcinoma. J Nucl Med. 2005;46(suppl 2):46P.
17. Keogan MT, Seabourn JT, Paulson EK, et al. Contrast-enhanced CT of intrahepatic and hilar cholangiocarcinoma: delay time for optimal imaging. AJR Am J Roentgenol. 1997;169:1493-1499.
18. Petrowsky H, Wildbrett P, Husarik D, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder and cholangiocarcinoma. J Hepatol. 2006;45:43-50.
19. Muller D, Weidmann M, Kluge R, et al. Is 18F-FDG-PET suitable for therapy monitoring after palliative photodynamic therapy of non-resectable hilar cholangiocarcinoma? Z Gastroenterol. 2005;43:439-443.